NSCLC靶向治疗发展到今天可以说是取得了一定的成就,新型靶向药物的研发层出不穷。除EGFR外,新的罕见分子靶点不断被检测,对应的靶向药物亦不断研发,临床试验并已显示出令人兴奋的结果和光明的前景。相信随着研究的不断深入,人们可能会重新定义靶向治疗在肺癌治疗中的作用,且靶向治疗可能最终改变肺癌的治疗模式,为治疗方案选择有限的患者带来希望。 参考文献:[1].Sung H, Ferlay J, Siegel R L, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA: a cancer journal for clinicians, 2021, 71(3): 209-249.[2].罗佳伟,吴凤英,周彩存.罕见驱动基因阳性非小细胞肺癌的治疗进展盘点[J].肿瘤综合治疗电子杂志,2019,5(2):29-33.[3].杨广建,王燕.非小细胞肺癌少见基因突变的治疗研究进展[J].癌症进展,2019,17(12):1371-1376,1418.[4].Planchard D, Besse B, Groen HJM, et al. Phase 2 Study of Dabrafenib Plus Trametinib in Patients With BRAF V600E-Mutant Metastatic NSCLC: Updated 5-Year Survival Rates and Genomic Analysis [published online ahead of print, 2021 Aug 26]. J Thorac Oncol. 2021;S1556-0864(21)02403-5.[5].周洁.NTRK基因融合和TRK抑制剂在非小细胞肺癌中的研究进展[J].中国肿瘤临床,2020,47(12):633-636.[6].Gainor JF, Curigliano G, Kim DW, et al. Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study [published correction appears in Lancet Oncol. 2021 Aug;22(8):e347]. Lancet Oncol. 2021;22(7):959-969.[7].李国雨,何明.非小细胞肺癌罕见靶点靶向治疗最新研究进展[J].协和医学杂志,2021,12(2):268-274.[8].Tong J H, Yeung S F, Chan A W H, et al. MET amplification and exon 14 splice site mutation define unique molecular subgroups of non–small cell lung carcinoma with poor prognosis[J]. Clinical Cancer Research, 2016, 22(12): 3048-3056.[9].Lu S, Fang J, Li X, et al. Once-daily savolitinib in Chinese patients with pulmonary sarcomatoid carcinomas and other non-small-cell lung cancers harbouring MET exon 14 skipping alterations: a multicentre, single-arm, open-label, phase 2 study. Lancet Respir Med. 2021;9(10):1154-1164.[10].Fang W, Huang Y, Hong S, et al. EGFR exon 20 insertion mutations and response to osimertinib in non-small-cell lung cancer. BMC Cancer. 2019;19(1):595.[11].Ramalingam SS, Zhou C, Kim TM, et al. Mobocertinib (TAK-788) in EGFR exon 20 insertion (Ex20ins)+ metastatic NSCLC (Mnsclc): Additional results from platinum-pretreated patients (Pts) and EXCLAIM cohort of phase 1/2 study. JCO. 2021;39(15_suppl):9014-9014. 审批编号:CN-93317本材料由阿斯利康提供,仅供医疗卫生专业人士参考 *此文仅用于向医学人士提供科学信息,不代表本平台观点